Facing a Crowded AMD Field, Alnylam Considers Dropping Drug Program, Focusing on Others | GenomeWeb

After Alnylam Pharmaceuticals' President and CEO John Maraganore announced last week that the company's wet age-related macular degeneration drug development program, the most advanced in its pipeline, might not proceed, investors reacted negatively. As of Thursday morning, about one week after news broke, the stock had lost about 10 percent of its value and was trading around $8.90.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.